Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
etanercept complement component 1q (c1q) biotech NA drugbank Rheumatoid Arthritis[MeSHID:D001172]
Ankylosing spondylitis[MeSHID:D013167]
Dental Plaque[MeSHID:D003773]
Senile Plaques[MeSHID:D058225]
Polyarthritis[MeSHID:D001168]
Arthritis
Psoriatic[MeSHID:D015535]
Psoriasis[MeSHID:D011565]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Sciatica[MeSHID:D012585]
Pemphigus Vulgaris[MeSHID:D010392]
Arthritis[MeSHID:D001168]		 NA approved,investigational ligand
etanercept complement component 1q (c1q) biotech NA drugbank Rheumatoid Arthritis[MeSHID:D001172]
Ankylosing spondylitis[MeSHID:D013167]
Dental Plaque[MeSHID:D003773]
Senile Plaques[MeSHID:D058225]
Polyarthritis[MeSHID:D001168]
Arthritis
Psoriatic[MeSHID:D015535]
Psoriasis[MeSHID:D011565]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Sciatica[MeSHID:D012585]
Pemphigus Vulgaris[MeSHID:D010392]
Arthritis[MeSHID:D001168]		 NA approved,investigational ligand
etanercept complement component 1q (c1q) biotech NA drugbank Rheumatoid Arthritis[MeSHID:D001172]
Ankylosing spondylitis[MeSHID:D013167]
Dental Plaque[MeSHID:D003773]
Senile Plaques[MeSHID:D058225]
Polyarthritis[MeSHID:D001168]
Arthritis
Psoriatic[MeSHID:D015535]
Psoriasis[MeSHID:D011565]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Sciatica[MeSHID:D012585]
Pemphigus Vulgaris[MeSHID:D010392]
Arthritis[MeSHID:D001168]		 NA approved,investigational ligand
etanercept high affinity immunoglobulin gamma fc receptor i biotech NA drugbank Rheumatoid Arthritis[MeSHID:D001172]
Ankylosing spondylitis[MeSHID:D013167]
Dental Plaque[MeSHID:D003773]
Senile Plaques[MeSHID:D058225]
Polyarthritis[MeSHID:D001168]
Arthritis
Psoriatic[MeSHID:D015535]
Psoriasis[MeSHID:D011565]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Sciatica[MeSHID:D012585]
Pemphigus Vulgaris[MeSHID:D010392]
Arthritis[MeSHID:D001168]		 NA approved,investigational ligand
etanercept low affinity immunoglobulin gamma fc region receptor ii-a biotech NA drugbank , DGIDB Rheumatoid Arthritis[MeSHID:D001172]
Ankylosing spondylitis[MeSHID:D013167]
Dental Plaque[MeSHID:D003773]
Senile Plaques[MeSHID:D058225]
Polyarthritis[MeSHID:D001168]
Arthritis
Psoriatic[MeSHID:D015535]
Psoriasis[MeSHID:D011565]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Sciatica[MeSHID:D012585]
Pemphigus Vulgaris[MeSHID:D010392]
Arthritis[MeSHID:D001168]		 3.35 approved,investigational ligand
etanercept low affinity immunoglobulin gamma fc region receptor ii-b biotech NA drugbank Rheumatoid Arthritis[MeSHID:D001172]
Ankylosing spondylitis[MeSHID:D013167]
Dental Plaque[MeSHID:D003773]
Senile Plaques[MeSHID:D058225]
Polyarthritis[MeSHID:D001168]
Arthritis
Psoriatic[MeSHID:D015535]
Psoriasis[MeSHID:D011565]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Sciatica[MeSHID:D012585]
Pemphigus Vulgaris[MeSHID:D010392]
Arthritis[MeSHID:D001168]		 NA approved,investigational ligand
etanercept low affinity immunoglobulin gamma fc region receptor ii-c biotech NA drugbank Rheumatoid Arthritis[MeSHID:D001172]
Ankylosing spondylitis[MeSHID:D013167]
Dental Plaque[MeSHID:D003773]
Senile Plaques[MeSHID:D058225]
Polyarthritis[MeSHID:D001168]
Arthritis
Psoriatic[MeSHID:D015535]
Psoriasis[MeSHID:D011565]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Sciatica[MeSHID:D012585]
Pemphigus Vulgaris[MeSHID:D010392]
Arthritis[MeSHID:D001168]		 NA approved,investigational ligand
etanercept low affinity immunoglobulin gamma fc region receptor iii-a biotech NA drugbank , DGIDB Rheumatoid Arthritis[MeSHID:D001172]
Ankylosing spondylitis[MeSHID:D013167]
Dental Plaque[MeSHID:D003773]
Senile Plaques[MeSHID:D058225]
Polyarthritis[MeSHID:D001168]
Arthritis
Psoriatic[MeSHID:D015535]
Psoriasis[MeSHID:D011565]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Sciatica[MeSHID:D012585]
Pemphigus Vulgaris[MeSHID:D010392]
Arthritis[MeSHID:D001168]		 0.98 approved,investigational ligand
etanercept low affinity immunoglobulin gamma fc region receptor iii-b biotech NA drugbank Rheumatoid Arthritis[MeSHID:D001172]
Ankylosing spondylitis[MeSHID:D013167]
Dental Plaque[MeSHID:D003773]
Senile Plaques[MeSHID:D058225]
Polyarthritis[MeSHID:D001168]
Arthritis
Psoriatic[MeSHID:D015535]
Psoriasis[MeSHID:D011565]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Sciatica[MeSHID:D012585]
Pemphigus Vulgaris[MeSHID:D010392]
Arthritis[MeSHID:D001168]		 NA approved,investigational ligand
etanercept lymphotoxin-alpha biotech NA drugbank Rheumatoid Arthritis[MeSHID:D001172]
Ankylosing spondylitis[MeSHID:D013167]
Dental Plaque[MeSHID:D003773]
Senile Plaques[MeSHID:D058225]
Polyarthritis[MeSHID:D001168]
Arthritis
Psoriatic[MeSHID:D015535]
Psoriasis[MeSHID:D011565]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Sciatica[MeSHID:D012585]
Pemphigus Vulgaris[MeSHID:D010392]
Arthritis[MeSHID:D001168]		 NA approved,investigational antibody
etanercept tumor necrosis factor biotech Successful target TTD , drugbank , DGIDB Rheumatoid Arthritis[MeSHID:D001172]
Ankylosing spondylitis[MeSHID:D013167]
Dental Plaque[MeSHID:D003773]
Senile Plaques[MeSHID:D058225]
Polyarthritis[MeSHID:D001168]
Arthritis
Psoriatic[MeSHID:D015535]
Psoriasis[MeSHID:D011565]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Sciatica[MeSHID:D012585]
Pemphigus Vulgaris[MeSHID:D010392]
Arthritis[MeSHID:D001168]		 1.28 approved,investigational antibody,inhibitor
etanercept tumor necrosis factor biotech Successful target TTD , drugbank , DGIDB Rheumatoid Arthritis[MeSHID:D001172]
Ankylosing spondylitis[MeSHID:D013167]
Dental Plaque[MeSHID:D003773]
Senile Plaques[MeSHID:D058225]
Polyarthritis[MeSHID:D001168]
Arthritis
Psoriatic[MeSHID:D015535]
Psoriasis[MeSHID:D011565]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Sciatica[MeSHID:D012585]
Pemphigus Vulgaris[MeSHID:D010392]
Arthritis[MeSHID:D001168]		 1.28 approved,investigational antibody
click here to return to the previous page